FRANKLIN LAKES, N.J. , Oct. 3, 2019 /PRNewswire/ -- BD ( Becton, Dickinson and Company ) (NYSE:BDX) announced today that it will conduct a live webcast of its fourth fiscal quarter and full fiscal year 2019 earnings conference call on Tuesday, November 5, 2019 , at 8:00 a.m. (ET) .

Independent analysis of LUTONIX® 035 Drug Coated Balloon patient-level data showed no statistically significant mortality increase     FRANKLIN LAKES, N.J. , Sept. 28, 2019 /PRNewswire/ -- BD ( Becton, Dickinson and Company ) (NYSE: BDX), a leading global medical technology company, today announced

Thomas E. Polen Appointed Chief Executive Officer, Effective Jan. 28, 2020   Vincent A. Forlenza to Continue as Executive Chairman of the Board     FRANKLIN LAKES, N.J. , Sept. 26, 2019 /PRNewswire/ -- BD ( Becton, Dickinson and Company ) (NYSE: BDX), a leading global medical technology company,

FRANKLIN LAKES, N.J. , Aug. 21, 2019 /PRNewswire/ -- BD ( Becton, Dickinson and Company ) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the following upcoming investor healthcare conferences: Wells Fargo Securities 2019 Healthcare Conference

BD appreciates the Food and Drug Administration’s (FDA) thoughtful, updated recommendations regarding the use of paclitaxel-coated devices following the Advisory Committee meeting of the Circulatory System Devices Panel in June. While the Panel concluded that a late mortality signal was present,

- As reported, revenues of $4.350 billion increased 1.7 percent. - On a comparable, currency-neutral basis, revenues increased 5.7 percent. - As reported, diluted earnings per share of $1.51 decreased 25.6 percent. - As adjusted, diluted earnings per share of $3.08 increased 5.8 percent, or 14.8